Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with relapsing multiple sclerosis (MS) who meet specific recognised diagnostic criteria, and who have had at least one MS relapse in the past year, or two relapses in the past two years, or at least one area of active inflammation visible on a brain scan (MRI) in the past six months
- People whose level of physical disability, measured on a standard MS scale, falls within a moderate range at the time of screening (confirm with trial site)
- Children and adolescents who have received all recommended childhood vaccinations as advised in their country
Who may not be able to join:
- People diagnosed with primary progressive MS, or a non-active form of secondary progressive MS
- People with certain other neurological, physical, or metabolic conditions that could interfere with the trial results
- People with a significant current psychiatric or medical illness
- People with a history of cancer, organ or tissue transplants, or bleeding disorders
- People who are unable to undergo an MRI scan or cannot receive the contrast dye used during MRI (called gadolinium)
- People with abnormal liver function test results or abnormal blood counts
- People with a known sensitivity or intolerance to any ingredient in the trial medication (fenebrutinib tablets)
- People with an active, recurring, or long-term infection
- People currently using, or expected to use, certain other MS treatments, immune-suppressing medications, specific drugs known to interact with the trial medication, other experimental therapies, blood-thinning medications, or certain vaccines (confirm with trial site for the full list)
- People who show certain signs of suicidal thoughts or behaviour based on standardised screening questionnaires, or who are considered by the investigating doctor to be at significant risk of suicide
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S.)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Plasma Concentration of Fenebrutinib; Total Number of New T1 Gadolinium (Gd)-enhancing Lesions on Brain Observed Through Magnetic Resonance Imaging (MRI) Scans
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.